MS and Demyelinating Disorders

The neurologist at Wayne State University provided background on why there needs to be a continued focus on including and studying African American patients with NMOSD in trials. [WATCH TIME 3 minutes]

Neuromyelitis optica patient Doug highlights the types of treatments he has received since his diagnosis and provides suggestions to patients on navigating therapy, especially during the COVID-19 pandemic.

Kim, a patient with neuromyelitis optica, describes what it has been like receiving rituximab infusions as preventive therapy, and shares advice for others who are about to embark on a similar treatment journey.

The clinical research director of the UCSF Multiple Sclerosis Center provided an overview on the state of care for NMOSD, specifically the development of inebilizumab, satralizumab, and eculizumab. [WATCH TIME: 6 minutes]

Here's what is coming soon to NeurologyLive.

The division chief of vascular neurology at the University of Utah discussed the individual role that clinicians and neurologists can play to increase interest in the field of neurology. [WATCH TIME: 2 minutes]

Neurology News Network for the week ending October 9, 2021. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 8, 2021.

Advice and resources for colleagues, including community practitioners and neurologists, to encourage collaboration and best support for patients with multiple sclerosis (MS).

An optimistic look at the future management of multiple sclerosis (MS) based on newer treatment options and ongoing research in the field.

Investigators suggest recognition of predictors can aid in directing future clinical trials, as well as inform early therapeutic decisions in this patient population.

Evanthia Bernitsas, MD, neurologist, Wayne State University, discussed a recently conducted analysis, which confirmed inebilizumab’s ability to treat African Americans with NMOSD.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Most attacks occurred within the first year of inebilizumab treatment, and nearly all participants were attack free in subsequent years following treatment initiation.

Data from 31,052 patients on the German Multiple Sclerosis Register were analyzed in the case-control study.

The neurologist at Wayne State University School of Medicine discussed recently published data describing inebilizumab’s role in producing rapid and sustained B-cell depletion in African Americans with NMOSD [WATCH TIME: 4 minutes]

Application follows the results of 2 independent, identical phase 3 trials, ULTIMATE 1 and 2, which assessed the TG Therapeutics anti-CD20 antibody in more than 1000 patients.

What to know about treating patients with neuromyelitis optica spectrum disorders throughout the COVID-19 pandemic.

An overview of newer preventive therapies approved for acute attacks of neuromyelitis optica spectrum disorders, and variables that impact treatment selection.

Here's what is coming soon to NeurologyLive.

Mitzi Joi Williams, MD, offered her perspectives on the patient and physician roles in MS care, the need for comprehensive care teams, resources for patients, and ongoing research.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 1, 2021.

Recommendations surrounding the use of complementary and natural therapies to manage symptoms of multiple sclerosis (MS).

Best practices for establishing treatment plans for patients with relapse-remitting multiple sclerosis (RRMS) and making decisions to switch therapies based on inadequate treatment responses, relapse, or disease progression.

As the MS patient population includes more patients from the millennial generation, the founder and CEO of the Joi Life Wellness Group Multiple Sclerosis Center offered her insight on the way care differs for this generation compared with prior ones. [WATCH TIME: 4 minutes]